R&D technology investments: misguided and expensive or a better way to discover medicines?
Authors:
- Esther F. SchmidESEsther F. Schmid
- Dennis A. SmithDSDennis A. Smith
- 1 September 2006
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 11 (17-18) , 775-784
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Critical review of the role of HTS in drug discoveryDrug Discovery Today, 2006
- Keynote review: Is declining innovation in the pharmaceutical industry a myth?Drug Discovery Today, 2005
- Overview of tyrosine kinase inhibitors in clinical breast cancerEndocrine-Related Cancer, 2005
- Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical TrialsJAMA, 2004
- HER2 Assessment by Immunohistochemical Analysis and Fluorescence In Situ HybridizationAmerican Journal of Clinical Pathology, 2002
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJournal of Clinical Investigation, 2000
- Chronic Myelogenous Leukemia: Biology and TherapyAnnals of Internal Medicine, 1999
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesBreast Cancer Research and Treatment, 1996
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987